The manufacturers of
tacrolimus say that during
clinical use ethinylestradiol has been shown to increase
tacrolimus levels, and
in vitro data suggests that gestodene and norethisterone may do the same.
Tacrolimus has the potential to interfere with the
metabolism of hormonal
contraceptives.
The manufacturers suggest that other (presumably non-hormonal) contraceptive measures should be used.